Published in Clinical Trials Week, June 6th, 2005
Scientists in England conducted a "randomized, double-blind, placebo-control led, cross-over study comparing the systemic pharmacodynamic effects (heart rate and serum potassium) and pharmacokinetics of salmeterol delivered by the non-CFC hydrofluoralkane (HFA) propellant 134a and the CFC propellant (propellant 11/12) metered dose inhalers (MDI) in healthy subjects."
"At the therapeutic dose (50 microg), salmeterol-mediated systemic pharmacodynamics were equivalent for the HFA and CFC MDIs," R. Kempsford and coauthors at GlaxoSmithKline Research & Development found....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.